{"name":"Adrienne G. Waks","slug":"adrienne-g-waks","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Trastuzumab and Hyaluronidase-oysk","genericName":"Trastuzumab and Hyaluronidase-oysk","slug":"trastuzumab-and-hyaluronidase-oysk","indication":"Adjuvant Treatment of HER2-Overexpressing Breast Cancer","status":"marketed"}]}],"pipeline":[{"name":"Trastuzumab and Hyaluronidase-oysk","genericName":"Trastuzumab and Hyaluronidase-oysk","slug":"trastuzumab-and-hyaluronidase-oysk","phase":"marketed","mechanism":"Trastuzumab inhibits HER2-overexpressing tumor cell proliferation and mediates ADCC, while hyaluronidase increases subcutaneous permeability for better drug absorption.","indications":["Adjuvant Treatment of HER2-Overexpressing Breast Cancer","First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer","Treatment of HER2-Overexpressing Metastatic Breast Cancer After Chemotherapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBJUlE4dXVPaWxEekFrdFRMR3dVcVpoYndHZlVCeVdMWE0xaFluRzdzNnRLMWcwWGZPZFllbTZNM1V2RW03RmNTbXRYX1p2cWctTG1JcDg1WVR0dHBxS1Fr?oc=5","date":"2025-11-28","type":"trial","source":"Nature","summary":"Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial - Nature","headline":"Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9JcjViU3ZtV2dVWUdFQXNfQVFGNDlmdk54RWtGSjFFZnZyQk95cUJNSTg4LTdTUzBfbkwxQkUxdGlKUFI4Z0ltS09nNmh6Zkg5YXZDOUJ2RHFxcUlWdXd3?oc=5","date":"2025-11-28","type":"pipeline","source":"Nature","summary":"Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer - Nature","headline":"Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive brea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPYTJobGs3VHhxZlNzd09VV0d0LWZFQWpPTXFOTW5hQTFORDFaYk9EVnFfd3FTVHA3RjRqNE5ZamZqNk1TYnRzU0RscEtnd3FJRjVqZVpYa0I5ZDhPbllKUTFBOFp2cTczeEhTZS1zak82S1ZoUnF3VFZsalVIMWRMRk1yRG5HcXZTeWQweVRPNXF5blRQVFJOemlvY2NsRlJVQmRaTWZDOGl3d3FBU1ZuTlZ4a0RVamU1VUd5MUYyQmhJVGZMWUJjY1JRUjlqWkZndmVIV2ZB?oc=5","date":"2025-03-05","type":"pipeline","source":"Healio","summary":"Subcutaneous adjuvant regimen for breast cancer reduces ‘time toxicity’ of treatment - Healio","headline":"Subcutaneous adjuvant regimen for breast cancer reduces ‘time toxicity’ of treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9mYVBpQXdLYm9TNFNPSkNVQVFZM29NUV9EXzlSc3pGUXVvSTNCRHZQdy1wZGZTdi13b0F3Z1ROaXA3eTg4d3A2T0pKYnc0d21SZFp1UHRneFlLa1RoVHY2bTI1UjBaWXRQUFczYi1CdU5BWWN3YnJVZmxBOA?oc=5","date":"2025-01-30","type":"trial","source":"Wiley","summary":"Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010–2019 - Wiley","headline":"Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the Surve","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5uSFgtN0wwdTk3Q3lNT243WTB3Sk9qaXotSzQta0I1YWtPcXZCWkFHSVhNTGIyU0hPSmRnNXRIbTk2d0hYTjliZmo5VmVxd0RhWXEyRExrM2N6aGtUX0dr?oc=5","date":"2024-04-04","type":"pipeline","source":"Nature","summary":"Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer - Nature","headline":"Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5tR3FlRTNNcFhlNWdlTzVtamZwR0cweXR2cWVpdHl4Y3lSRldwSzk3d1BfckdxTFkzS3NBdXNLT0hubElNZmpuaWNXc2M5R2VOczhCWGVHS2pVZHVCLWhR?oc=5","date":"2022-05-10","type":"trial","source":"Nature","summary":"A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer - Nature","headline":"A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive ","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}